Immunome, Inc. (IMNM) announced on Tuesday that it has signed a definitive asset purchase agreement to acquire AL102 and its related drug candidate AL101 from Ayala Pharmaceuticals, Inc.
According to the agreement, Ayala will receive $20 million in cash and $30 million in Immunome common stock. Immunome will also make further payments of up to $37.5 million for development and commercial milestones. The transaction is subject to customary conditions.
Immunome's President and Chief Executive Officer, Clay Siegall, said "AL102 will complement our existing portfolio of targeted cancer agents that are approaching Phase 1 trials. As we complete the work required to advance AL102 to NDA submission, we also plan to investigate other populations of cancer patients that could benefit from treatment with AL102."
AL102 is a promising once-daily oral treatment for desmoid tumors that is currently being evaluated in the randomized Phase 3 RINGSIDE international trial.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.